LY-266,097

LY-266,097 is a pharmacological compound that acts as a selective, non-competitive antagonist at the glutamate receptor, specifically the mGluR1 subtype. It has been used in scientific research to investigate the role of mGluR1 in various physiological and pathological processes.

Pharmacology

LY-266,097 is a drug that selectively inhibits the mGluR1 receptor. This receptor is a type of metabotropic glutamate receptor, which are G protein-coupled receptors that respond to the neurotransmitter glutamate. By blocking the action of glutamate at this receptor, LY-266,097 can modulate the activity of neurons in which mGluR1 is expressed.

Uses in Research

The selective action of LY-266,097 on mGluR1 has made it a useful tool in neuroscience research. It has been used to investigate the role of mGluR1 in various processes, including neurotransmission, synaptic plasticity, and the pathophysiology of conditions such as schizophrenia and Parkinson's disease.

Pharmacokinetics

The pharmacokinetics of LY-266,097, including its absorption, distribution, metabolism, and excretion, are not well characterized. As a research compound, it is typically administered directly to experimental animals, and its effects are observed over a period of time.

Safety and Toxicity

The safety and toxicity of LY-266,097 have not been extensively studied. As a research compound, it is not intended for use in humans. Researchers working with this compound are advised to take appropriate safety precautions.

See Also

• Metabotropic glutamate receptor
• Glutamate (neurotransmitter)
• Neurotransmission
• Pharmacology

This article is a stub related to pharmacology. You can help WikiMD by expanding it!